48
Participants
Start Date
December 4, 2019
Primary Completion Date
June 24, 2022
Study Completion Date
June 24, 2022
LY3471851
Administered SC
Placebo
Administered SC
DermDox Centers for Dermatology, Sugarloaf
Paddington Testing Company Inc, Philadelphia
Medical Dermatology Specialists, Sandy Springs
Miami Dermatology and Laser Research, Miami
Skin Sciences, Louisville
Remington-Davis, Inc, Columbus
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Derm Center, Troy
Arkansas Research Trials, LLC, North Little Rock
Unity Clinical Research, Oklahoma City
Rodgers Dermatology, Frisco
Studies in Dermatology, LLC, Cypress
Complete Dermatology, Sugar Land
Progressive Clinical Research, San Antonio
Clinical Science Institute, Santa Monica
California Dermatology & Clinical Research Institute, Encinitas
Therapeutics Clinical Research, San Diego
Center For Dermatology Clinical Research, Inc., Fremont
ForCare Clinical Research, Tampa
ActivMed Practices and Research, Portsmouth
Lead Sponsor
Eli Lilly and Company
INDUSTRY
Nektar Therapeutics
INDUSTRY